ES2334149T3 - Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. - Google Patents

Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. Download PDF

Info

Publication number
ES2334149T3
ES2334149T3 ES05706024T ES05706024T ES2334149T3 ES 2334149 T3 ES2334149 T3 ES 2334149T3 ES 05706024 T ES05706024 T ES 05706024T ES 05706024 T ES05706024 T ES 05706024T ES 2334149 T3 ES2334149 T3 ES 2334149T3
Authority
ES
Spain
Prior art keywords
vtmr
tenofovir
agents
breast cancer
adefovir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05706024T
Other languages
English (en)
Spanish (es)
Inventor
Tomas Cihlar
Janet L. Douglas
Craig S. Gibbs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2334149T3 publication Critical patent/ES2334149T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
ES05706024T 2004-01-21 2005-01-21 Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria. Expired - Lifetime ES2334149T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53806604P 2004-01-21 2004-01-21
US538066P 2004-01-21

Publications (1)

Publication Number Publication Date
ES2334149T3 true ES2334149T3 (es) 2010-03-05

Family

ID=34825960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05706024T Expired - Lifetime ES2334149T3 (es) 2004-01-21 2005-01-21 Uso de adefovir o tenofovir para inhibir virus de tipo vtmr implicados en el cancer de mama y en la cirrosis biliar primaria.

Country Status (10)

Country Link
US (2) US20070281911A1 (cg-RX-API-DMAC7.html)
EP (1) EP1732569B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007518815A (cg-RX-API-DMAC7.html)
AT (1) ATE445404T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005209256B2 (cg-RX-API-DMAC7.html)
CA (1) CA2553455A1 (cg-RX-API-DMAC7.html)
DE (1) DE602005017131D1 (cg-RX-API-DMAC7.html)
ES (1) ES2334149T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ548532A (cg-RX-API-DMAC7.html)
WO (1) WO2005072748A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1879657A2 (en) * 2005-04-25 2008-01-23 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of compounds to enhance processivity of telomerase
RU2301088C2 (ru) * 2005-09-01 2007-06-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ лечения рецидива рака молочной железы
ATE534377T1 (de) 2006-05-16 2011-12-15 Gilead Sciences Inc Verfahren und zusammensetzungen zur behandlung von hämatologischen erkrankungen
ES2566762T3 (es) * 2009-10-05 2016-04-15 Ambergen Inc. Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
US9089574B2 (en) 2011-11-30 2015-07-28 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
KR102196711B1 (ko) * 2018-08-30 2020-12-30 가톨릭대학교 산학협력단 테노포비르 디소프록실 푸마르산을 유효성분으로 함유하는, 간섬유증 예방 또는 치료용 약학적 조성물
WO2020171225A1 (ja) * 2019-02-22 2020-08-27 一素 村田 mTOR阻害剤
US12029783B2 (en) 2019-07-02 2024-07-09 Virago Vax Inc. Mammary tumor virus vaccine
US12016844B2 (en) 2019-07-02 2024-06-25 Virago Vax Inc. Mammary tumor virus suppression
EP3993873A4 (en) * 2019-07-02 2023-09-20 Virago Vax Inc. SUPPRESSION OF BREAST TUMORS
CN119546620A (zh) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 用于治疗疾病的化合物和方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073507A2 (en) * 1999-06-01 2000-12-07 Alton Ochsner Medical Foundation Identification of a novel retrovirus associated with primary biliary cirrhosis and autoimmune disorders
ATE399204T1 (de) * 1999-06-30 2008-07-15 Univ Tulane Humanes endogenes retrovirus
HRP20030047B1 (hr) * 2000-07-21 2016-02-26 Gilead Sciences, Inc. Prolijekovi koji su fosfonatni analozi nukleotida i metode njihovog odabira te njihova priprava
IL164809A0 (en) * 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues

Also Published As

Publication number Publication date
ATE445404T1 (de) 2009-10-15
CA2553455A1 (en) 2005-08-11
EP1732569B1 (en) 2009-10-14
US20050239753A1 (en) 2005-10-27
HK1099228A1 (en) 2007-08-10
AU2005209256B2 (en) 2010-11-18
AU2005209256A1 (en) 2005-08-11
EP1732569A1 (en) 2006-12-20
JP2007518815A (ja) 2007-07-12
WO2005072748A1 (en) 2005-08-11
US20070281911A1 (en) 2007-12-06
DE602005017131D1 (de) 2009-11-26
NZ548532A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
ES2785034T3 (es) Métodos para el tratamiento de infecciones de virus de filoviridae
ES2918585T3 (es) Métodos para el tratamiento de infecciones por el virus Arenaviridae
ES2409755T3 (es) Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
ES2660263T5 (en) Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
EP1732569B1 (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
TR201906416T4 (tr) Hiv inhibitörü bileşiklerin fosfonat analogları.
US20230277566A1 (en) Broad spectrum antiviral and methods of use
ES2910049T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
WO2023167938A1 (en) Compounds and methods for treatment of viral infections
KR20170134462A (ko) Mdm2 저해제와 btk 저해제의 병용 치료법
US20220088042A1 (en) Combination therapy including sapc-dops for the treatment of pancreatic cancer
ES2969239T3 (es) Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
CN101959407A (zh) 4’-硫-2’-去氧核苷作为抗正痘病毒剂的用途
KR100632520B1 (ko) Β 형 간염 바이러스를 치료하기 위한 복합 요법
ES2747073T3 (es) Combinación de RO5503781, capecitabina y oxaliplatino para el tratamiento del cáncer
WO2011046901A2 (en) Broad spectrum antiviral and methods of use
HK1099228B (en) Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
KR20050042134A (ko) B형 간염 바이러스 감염의 치료를 위한 l-fmau를사용한 병용 치료
HK1258795B (en) Methods for treating filoviridae virus infections
Mannhold et al. Antiviral Drug Strategies
HK1242569A1 (en) Methods for treating filoviridae virus infections
HK1242569B (en) Methods for treating filoviridae virus infections